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CHEMISTRY OF BOWEN'S DISEASE: RELATIONSHIP TO
ARSENIC *
JAMES H. GRAHAM, M.D., GIOVANNA R. MAZZANTI, Pn.D. AND ELSON B.
HELWIG, M.D.
In 1959 and 1961 two of us (1, 2) reported a
previously unrecognized association of Bowen's
disease of the skin with primary internal cancer.
The purpose of this report is to present data
which strongly suggest arsenic as one of the
causes of Bowen's disease and the associated
internal cancer.
In 1959 (1) we reviewed material from 15
patients with keratosis and a definite history of
ingestion or contact with arsenic, such as Fowler's
solution, arsenate of lead, arsenious acid and
other injectiblc and oral compounds. Clinically
and histologically these arsenical keratoses were
practically indistinguishable from those of
Bowen's disease (Figs. 1—6). Furthermore, a
comparison of the natural history of patients
with Bowen's disease and those with prolonged
contact or treatment with the inorganic arsenicals
showed a striking similarity. The average latent
period of 6 to S years from onset of the Bowen's
lesion until cutaneous and internal cancer appears
is characteristic of the long latent interval of
carcinogenic action of arsenic, as reported by
Neubauer (3), Sommers and MacManus (4),
Roth (5) and others. However, in our patients
with Bowen's disease there was no detectable
history of ingestion or external exposure to
arsenic, except in five patients who gave a his-
tory of syphilis and subsequent treatment with
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agents such as Salvarsan, Neoarsphenamine and
Tryparsamide. Because of these similarities of
Bowen's disease and arsenical keratosis and their
association with systemic cancer, we wondered
about arsenic as a common etiologic agent. Some
of the similarities of the two diseases were pointed
out by Anderson (6) in 1932, although data
sufficient for statistical evaluation have never
been available. Since arsenic is a known powerful
chemical carcinogen and is widely distributed in
nature, we proposed to investigate its presence
or absence in lesions of a large group of patients
with Bowen's disease
MATERIAL AND METHODS
This study was conducted at the Skin and
Cancer Hospital of Philadelphia and the Armed
Forces Institute of Pathology, Washington, D. C.
Our material consisted of Bowen's skin lesions
from various sites from 50 adult patients. Most
of the patients did not give a detectable history
of contact with arsenic. The duration of the lesions
from onset to excision or biopsy varied from 6
months to 24 years. The average was 6.4 years.
The average age of the 50 patients at onset of
Bowen's disease was 48 years. Skin adjacent to the
Bowen's lesion was available for study in 30
patients. For comparison and controls, material
was examined from 126 patients with the following
diseases: arsenical keratosis, 7; basal-cell car-
cinoma, 23; senile keratosis, 17; intraepidermal
epithelioma of Jadassohn, 13; extramammary
Paget's disease, 11; scborrheic keratosis, 7;
erythroplasia of Queyrat, 6; adcnoacanthoma, 5;
benign cellular nevi, 4; kcratoacanthoma, 4;
multiccntric basal-cell carcinoma, 3; squamous-
cell carcinoma, verruca vulgaris, normal skin,
fibroepithclial polyp, epidermoid cyst and derma-
tofibroma, 2 each; hemangioma, juvenile xantho-
granuloma, xanthoma tuberosum, epidcrmolysis
bullosa hereditaria letalis, balanitis xerotica
obliterans, ncurofibroma, adnexal carcinoma,
angiolipoma, psoriasis, pscudoepitheliomatous
hyperplasia, dermatofibrosarcoma protubcrans,
melanoma, cpithclial nevus and pilomatrixoma,
1 each. Skin adjacent to the control lesions was
available for study in 38 patients. The 7 patients
with arsenical kcratosis and the five in the Bowen's
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FIG. 1. Bowen's lesion appearing as erythematous, scaly, fissured, keratotic, nodular, plaque-like
lesion sharply demarcated from the surrounding tissue. (AFIP Neg. 60-4979).
FiG. 2. Keratotic lesion from a patient treated with Fowler's solution 20 years before onset of the
lesion. With clinical features of Bowen's disease the lesion appears erythematous, scaly, fissured, kera-
totic, irregular, plaque-like and sharply demarcated from the surrounding tissue. (AFIP Neg. 58-9643).
FIG. 3. Bowen's lesion with plaque-like acanthosis, hyperkeratosis, parakeratosis and involvement
of a pilosebaceous follicle. An inflammatory infiltrate of lymphocytes and plasma cells is seen in the
upper corium. X 50 (AFIP Ace. 324186, Neg. 58-7561).
disease group already mentioned received arsenic. Sections stained with hematoxylin and eosin
Only one patient in the control group was known were examined from all lesions in the Bowen's
to have received arsenical therapy. Mapharsen and the control groups.
was administered for syphilis 10 years before onset The chemical analyses for arsenic were carried
of a penile lesion of erythroplasia of Queyrat. out on tissues fixed in 10% formalin and digested
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FIG. 4. High power of area from Fig. 3 showing loss of normal architecture and cellular atypism in the
form of multinucleated cells, vacuolated cells, dyskeratosis and mitotic figures. X 305 (AFIP Ace.
324186, Neg. 58-7560).
FIG. 5. Arsenical keratosis with plaque-like acanthosis, spotted parakeratosis and a mild inflammatory
infiltrate of lymphocytes and plasma cells in the upper corium. X 115 (AFIP Ace. 303800, Neg. 58-7952).
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Fm. 6. High power of area from Fig. 5 showing features of Bowen's disease: loss of normal architec-
ture, and cellular pleomorphism in the form of hyperehromatic nuclei, multinucleated cells, vacuolated
cells, and mitotic figures. The changes are present at all levels of the epidermis. X 395 (AFIP Ace.
303800, Neg. 58-7953).
in a mixture of sulfuric and nitric acids. Arsenic
was distilled from this mixture as arsine and then
determined by the development of the hetero-
polyblue compound formed by condensation of
arsenate and molybdate ions and reduction of this
complex by hydrazine sulfate. The absorbance
was read with a Beckman Model D1J spectro-
photometer. The method (7—10) is reliable and
acceptable for accuracy. Several samples of
formalin fixative were analyzed to rule out the
possibility that arsenic was leached out of the
tissue. No significant amounts of arsenic were
present. Determinations on fresh tissue from
Bowen's lesions gave values comparable to those
found on the formalin-fixed material used in this
study.
The normal ranges for arsenic established with
our method were between 0.0 and 1.0 pg/g of wet
weight. These figures were comparable to those
determined by Scott (11) and Fergusson et at. (12),
using neutron activation analysis for the quanti-
tative determination of arsenic, and also in agree-
ment with figures generally accepted by toxicolo-
gists. All of our data were statistically evaluated
by utilizing the Chi-square test and other tests
of significance.
RESULTS
Chemistry: Our data indicate that in lesions of
Bowen's disease and the adjacent normal skin,
arsenic is present in a significantly greater amount
than in the control lesions (Chart 1). These
results do not include the group of patients with
arsenical keratoses. Tn 70.6% of the controls the
lesion had normal values (0.0-1.0 ,ug/g wet tissue)
but in only 18% of the Bowen's patients did the
lesions fall into this range. The difference was
highly significant (Chi-square = 39.344). In the
highest range, 22% of the Bowen's lesions con-
tained arsenic values of 10 or more pg/g whereas
similar values were noted in only 5.0% of the
control lesions. This difference was also highly
significant.
High values of arsenic did not appear to be
directly related either to anatomic site or to the
interval from onset to excision of the lesions.
Five of the 9 patients with normal arsenic values
in lesions of Bowen's disease had had the disease
for 10 to 28 years; in contrast, 4 of 7 with values
15 b'g/g or higher had had it for 3 years or less.
Skin immediately adjacent to the lesion and
z0
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Arsenic Values in Bowen's Disease and Controls
(Cutaneous Lesions)
not histologically involved with the disease
process was available from 30 patients with
Bowen's disease and 38 controls. Fifty and 18
per cent, respectively, had higher arsenic values
in the lesion than in the adjacent skin; only 4
(13%) of the Bowen's disease lesions had normal
arsenic values in both lesion and adjacent skin,
as compared with 28 (74%) of the controls
(Tables 1 and 2). Both these differences were
statistically significant. The odds are 1999:1
(Chi-square = 28.291) that a distribution that
would yield a Chi-square value as great as or
greater than 12.8 could occur by chance in a
sampling. Thus, patients with Bowen's disease
are more likely than the controls to have higher
arsenic values in the lesion than in adjacent skin
and less likely to have normal arsenic values in
both lesion and adjacent skin. One patient had a
lesion of Bowen's disease geographically adjacent
to a basal cell carcinoma and both were excised
together. Each lesion and the adjacent skin had
higher than normal arsenic values; however, the
Bowen's lesion had approximately five times the
TABLE 1
Comparative values of arsenic in lesions and
adjacent skin
Lesion vs. Adjacent Skin BOWeUS Con..
All patients 30 38
Lesions
Normal
Above normal
Normal
Above normal
Higher
Lower
Same
Adjacent Skin
Normal
Normal
Above normal
Above normal
Lower
Higher
Same
11
4
7
—
19
8
10
1
36
28
6
2
2
1
1
—
NoTE: "Higher" and "lower" signify the com-
parative arsenic values in the lesions and the
corresponding adjacent skin.
amount contained in the basal cell carcinoma—
15 and 3.70 zg/g, respectively. The arsenic value
in the adjacent skin of the patient was 9.97
'BOWENS DISEASE (50 PATIENTS)
9"SC0NTROLS (119 PATIENTS)
AS WET WEIGHT
CHART 1. Arsenic values in Bowen's disease and controls (cutaneous lesions)
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TABLE 2
Arsenic values in. lesions and adjacent skin1
Arsenic Values, g/g Wet Tissue
Lesions Adjacent Skin
Number Per Cent Number in
Bowen's Control Bowen's Control Bowen's Control
Total patients 50 119 100 100 30 38
Normal (1.00 & less)
1.01—4.99
5.00—9.99
10.00—14.09
15.00 and over
9
24
6
4
7
84
28
1
2
4
18
48
12
8
14
71
23
1
2
3
11
15
3
1
—
34
3
1
—
—
1 Highest values found in multiple lesions were used.
g/g. In 38 patients in the control group, skin
adjacent to the lesion was analysed for arsenic
and the breakdown is as follows: 28 patients had
normal values both in the lesion and adjacent skin
(Table 1); 6 had an elevated arsenic content in
the lesion and normal values in the adjacent
skin. Two had normal values in the lesions and a
higher than normal arsenic content in the ad-
jacent skin; and 2 had arsenic values higher than
normal both in the lesion and adjacent skin.
The diagnoses are related to the higher than
normal values in Table 3.
In 3 patients with Bowen's disease, multiple
lesions were available for chemical analysis.
One patient had increased arsenic values in the
same range in all lesions; the 2 others had normal
values in some lesions and higher than normal
in others (Table 4). In 10 patients in the control
group multiple lesions were available for analysis.
Eight had normal values in all lesions, whereas
2 patients had normal values in 1 lesion and
higher than normal in others (Table 5).
In 5 patients with adenoacanthoma, 4 lesions
had normal arsenic values, whereas one had
arsenic values higher than normal. This latter
patient was known to have Bowen's disease but
no tissue representing the disease was available
for analysis (Table 6).
In 17 patients of the control group with senile
keratosis, 10 had arsenic values higher than
normal in their lesions (Table 6). This proportion
is lower than in the patients with Bowen's
disease and is significant at just under the 5%
level of probability (Chi-square = 3.756).
TABLE 3
Diagnoses related to above-normal arsenic values
in adjacent skin of control patients
Diagnosis
Arsenic Values, g/g
Wet Tissue
Lesion Adj. skin
Total with both tissues
Normal values in skin
38
34
Basal-cell carcinoma
Basal-cell ca., multicentric
Intraepidermal epithelioma....
Adnexal carcinoma
1.00 5.16
0.51 2.69
3.60 5.04
3.50 3.05
TABLE 4
Bowen's disease—arsenic values in multiple
lesions of same patient
Pt. No. Site
Arsenic Values, pg/g
Wet Tissue
Lesion Adjacent skin
2
16
43
Shoulder
Hip
Thigh
Breast
Arm
Leg
Midback
Calf
Hand
Rt. side
Thigh
3.81
4.44
1.13
1.04
1.00
4.0
3.33
4.84
3.27
3.15
3.05
—
0.55
0.50
0.62
0.50
1.00
1.04
0.50
2.63
0.87
0.39
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TABLE 5
Arsenic values in multiple lesions of
same patient—controls
Diagnosis Site
Arsenic
pg/g Wet
Lesion
Values,
Tissue
Adja-
cent
skin
Basal-cell carcinoma
Basal-cell carcinoma
Eyelid
Cheek
Neck
Chin
050
1.00
0.50
1.00
—
1.00
0.50
1.00
Senile keratosis Nose
Hand
Neck
1.00
1.00
1.00
1.00
1.00
1.00
Adenoacanthoma Ear
Cheek
1.00
1.00
—
—
Neurofibroma Sacral 0.50 1.00
Epidermoid cyst
area
Chest
Scalp
Scalp
Scalp
1.00
0.50
0.50
0.50
—
1.00
0.50
—
Intradermal nevus Forehead
Groin
0.50
0.50
—
—
Extramammary Penis 0.34 0.26
Paget's dis. Penis 0.13 0.06
Basal-cell carcinoma Cheek 17.40 —
(multicentric) Forehead 3.00 —
Temple 1.00 —
Balanitis xerotica Foreskin 0.50 0.50
obliterans Foreskin 13.00 —
Of 7 patients with arsenical kei atosis, 2 had
lesions and adjacent skin with arsenic values
higher than normal. Four had lesions with
normal values and 1 of these also had normal
values in adjacent skin. In 1 patient normal
values were noted in some lesions and higher
than normal in others (Table 7). A Chi-square
test indicates that the proportions of patients
with Bowen's disease and with arsenical kera-
tosis do not differ significantly with respect to
the presence of normal versus higher than nor-
mal arsenic values.
Microscopic Examination: Microscopic descrip-
tion of typical Bowen's disease has been pre-
sented in previous reports (1, 2). Variability
of changes in the same lesion as well as between
lesions has been noted. This was emphasized
during the examination of multiple sections from
the same lesion and in studying microscopic
Basal-cell carcinoma.
Seborrheic keratosis..
Senile keratosis
Adenoacanthoma
Basal-cell ca., multi-
centric
Extramammary Paget 's
disease
Intraepidermal epithe-
lioma
Normal skin
Keratoacanthoma
Epithelial nevus
Cellular nevus
Squamous-cell carci-
noma
Hemangioma
Juvenile xanthogranu-
loma
Verruca vulgaris
Xanthoma tuberosum..
Fibroepithelial Polyp..
Pilomatrixoma
Epidermolysis bullosa
Balanitis xerotica oh-
literans
Neurofibroma
Epidermoid cyst
Psoriasis
Dermatofibroma
Erythroplasia of
Queyrat
Adnexal carcinoma....
Angiolipoma
Pseudoepitheliomatous
hyperplasia
Dermatofibrosarcoma
protuberans
Leukoplakia with squa-
mous-cell ca
Melanoma
1 This patient also had Bowen's disease.
TABLE 6
Arsenic values in various diseases—controls
Arsenic Values. pg/g
Wet Tissue
Diagnosis TotalPatients 1.00 1.01 5.00 iti.m
or
less
84
to
4.99
28
to
9.99
1
or
more
6Total 119
1
6
9
3
3
1
1
1
2
2
1
1
1
11
1
1
1
23
7
17
5
3
11
13
2
4
1
4
1
1
1
2
1
2
1
1
1
1
2
1
2
6
1
1
1
1
1
1
17
5
7
4
2
8
10
2
3
1
4
1
1
1
1
1
2
1
1
2
1
3
1
1
1
1
1
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TABLE 7
Arsenical Iceratosis—arsenic values in single and
multiple lesions of same patient
Pt. No. Site
Arsenic Vslues, g/g Wet Tissue
Lesion Adjscent skin
1 Abdomen
Arm
Heel
Wrist
Arm
Abdomen
Abdomen
0.50
0.50
0.77
0.81
6.45
3.12
1.13
0.20
0.52
0.50
0.50
2 Foot
Foot
Foot
Foot
Foot
Hand
Hand
Hand
Hand
0.20
0.40
0.20
0.40
0.40
1.02
0.20
0.76
0.30
0.20
0.40
0.40
—
—
0.30
—
—
—
3 Trunk 1.00 —
4 Scrotum 0.60 —
5 Hand 0.60 —
6 Chest 2.83 11.05
7
Leg
Back
Leg
Umbilicus
59.09
41.90
144.30
8.80
—
—
12.88
3.35
material of lesions of Bowen's disease from over
600 patients. A striking feature is involvement
of the pilosebaceous follicle in lesions from all
areas where Bowen's disease of the skin is found
except the palms and soles (Figure 7). Atypical
epithelial alterations appear to start in the
undifferentiated cells of the external root sheath
of the pilosebaceous apparatus and at this
site the vacuolated cells which are normally
present become involved in the proliferating
process (Fig. 5). The abnormal vacuolated cells,
along with others from the epithelial outer root
sheath and sebaeeous gland, are probably pushed
inward and upward in the proliferating process
and appear similar within the epidermis (Figs.
3, 4, 7—9). The process was not observed to in-
volve the ecerine sweat duet unit, although its
course as it passes through the epidermis may
be straightened (Figs. 10, 11). Occasionally
areas of uninvolved epidermis are observed.
The atypical epithelial proliferation may extend
deep into the corium and still not represent
invasive carcinoma as long as it remains within
the boundaries of the fibrous outer root sheath.
In most instances identifiable remnants of the
pilosebaceous follicle are present, although in
some examples the normal architecture is com-
pletely destroyed and replaced by abnormal
epithelial cells.
REvvEW OF THE LITERATURE
Neubauer (3) in 1947 reviewed the literature
regarding Bowen's disease and its relationship to
arsenic. The evidence accumulated at that time
was contradictory and variable, leaving the issue
unsettled. Studies by Montgomery and Waisman
(13), Frank (14), Scott (11), Domonkos (15)
and Fergusson et al. (12) disclosed results of
chemical analysis for arsenic on a variety of
cutaneous premalignant and malignant lesions,
including Bowen's disease and arsenical keratosis.
Montgomery and Waisman (13) in 1941 noted
generally more arsenic within arsenical epi-
theliomas than in the adjacent skin and con-
firmed the conclusion reached by Montgomery
(16) in 1935. Frank (14) in 1950 analyzed intact
skin from the left arm, a lesion of Bowen's
disease from the chest, and a "spinobasocellular"
carcinoma of the scrotum of a patient with
industrial arsenic exposure. He observed a
striking deviation in the arsenic content of the
3 specimens. The intact skin contained normal
amounts of arsenic and the Bowen's lesion had
approximately 25 times more arsenic than the
carcinoma. More recently, Scott (11) also noted
that patients exposed to arsenic either through
ingestion or by external contact who later de-
veloped keratosis and epitheliomas tend to have
a higher than normal content of arsenic, not
only in the actual lesion, but also in their normal
skin. The content of arsenic was greater in
those sites in which lesions had developed than
in the rest of their skin. His results varied from
patient to patient and among different lesions
from the same patient. Domonkos (15), in
contrast, stated, "there is no significant dif-
ference in the amount of arsenic between arsenical
epitheliomas and epitheliomas in patients with
no arsenic history. In the majority of the eases
there is less arsenic in the epithelioma than in
the adjacent normal skin, not only in arsenical
epithelioma but also in epithelioma without
arsenic history." Domonkos (15) analyzed (by
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FIG. 7. Bowen's lesion with hyperkeratosis, parakeratosis, aeanthosis, and involvement of the pilose-
baceous follicle. The epithelial cells appear similar at all sites. In the upper eorium there is vascular
ectasia and senile elastosis. X 50 (AFIP Ace. 698592, Neg. 58-7812).
FIG. 8. Higher power of Fig. 7 showing cellular atypism of the cells of the epithelial outer root sheath.
Vacuolated cells are present adjacent to a remnant of hair and parakeratotic material. X 305 (AFIP
Ace. 698592, Neg. 58-7813).
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FIG. 9. Bowen's lesion showing cellular atypism of the epithelial outer root sheath and sehaceous
gland. X 305 (AFIP Acc. 699244, Neg. 58-8775).
Fio. 10. Bowen's lesion showing epidermal ecerine sweat duct which is uninvolved except for its
straight course and keratotic plug. X 100 (AFIP Acc. 809353, Neg. 58-9134).
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FIG. 11. Higher power of area from Fig. 10. The epithelium of the ecerine sweat duct is sharply de-
marcated from the atypical Bowen's cells. A few keratohy]in granules are seen in the sweat duct. X
575 (AFIP Ace. 809353, Neg. 58-9133).
neutron activation) five lesions of Bowen's
disease from patients with arsenic history and
two lesions from patients without such a history.
The determinations were within his established
normal range. He noted a wide range of values
in specimens from the same patient both with
and without a history of arsenic intake. Fergus-
son et al. (12) in 1960 reported data obtained in
an investigation of 106 patients who were suf-
fering from various skin diseases generally
accepted as similar to those produced by arsenic
poisoning. In six patients with Bowen's disease
the arsenic content of the lesions was within the
recognized normal limits (0.0—1.0 g/g wet
weight). He concluded that arsenic was not
present in abnormal amounts in any of the
conditions studied except in those patients with
a known history of arsenic medication.
COMMENT
Because of the striking similarities of Bowen's
disease and arsenical keratosis it is our opinion
that in many instances arsenic is probably also
an etiological factor of Bowen's disease. This
would account for the cancer proneness and
especially the high incidence of internal malignant
neoplasms in patients with Bowen's disease. A
history of ingestion of, or exposure to, arsenic
is not always obtainable, even in the presence
of unimpeachable evidence of arsenic sequelae.
Our study illustrates this unreliability of history
from the patient, since the presence or absence
of arsenic in lesions of Bowen's disease, arsenical
keratosis, and those from the control group
could not be related to either a positive or nega-
tive history. Neither does the demonstration of
arsenic by chemical methods prove that the
element is an etiological factor in a given case,
nor does its absence exclude arsenic as a causa-
tive factor. However, the presence of increased
values of arsenic in 82% of the Bowen's lesions
as compared to only 30% in the control lesions
is of striking statistical significance. The question
arises as to how the Bowen's patient and those
in the control group were exposed to arsenic.
Several factors might account for the increased
amounts of arsenic present in our group of
patients. The average age of the patient at the
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time of onset of Bowen's disease was 45 years.
Therefore, these patients had been living in a
period in which arsenical preparations were
used medicinally as tonics, and in treatment of
such diseases as chronic malaria, anemia, asthma,
dermatitis herpetiformis, lichen planus, chronic
discoid and lichenoid dermatosis, scrofula, chronic
eczema, acne, psoriasis, neurodermatitis, chorea,
migraine, epilepsy, rheumatic fever, and syphilis.
Furthermore, up to 1946, when organic insec-
ticides began to be used in the United States, it
was a regular practice to spray tobacco fields
and other agricultural crops with arsenate of
lead and other arsenical preparations. Much
of this undoubtedly leached into the soil and is
being absorbed into the plants and food now
being grown. According to Satterlee (17), the
arsenic content of cigarettes made from American
tobacco increased from 12.6 jig per cigarette in
1932 to 42 pg by 1951. Finally, a study of out-
door air samples in both rural and urban loca-
tions revealed a much higher arsenic content in
city air. City arsenic is associated with smoke,
soot and tar, and probably comes mostly from
the combustion of fossil fuels. In the country
air, the arsenic is particularly found associated
with pollen, insects and organic matter.
On the basis of our study the Bowen's lesion
and the arsenical lesion seemed to concentrate
arsenic more than the majority of other lesions.
This observation is supported by the reports of
Montgomery (16), Montgomery and Waisman
(13), Frank (14), Scott (11), and Fergusson
et al. (12). The affinity of arsenic for keratin-
producing epithelial structures of the skin is
well recognized. The histopathologie changes of
Bowen's disease suggest that the undifferentiated
cells of the epithelial outer root sheath are
affected, and this seems logical since the pilar
structure is a rich keratin producer. The ability
of the Bowen's lesion to concentrate arsenic is
probably based on abnormal cellular metabolism.
The arsenic is most likely localized intraeellularly
in the conjugated form, bound either to nucleic
acid or to other cellular elements to which it
may have an affinity. Warburg (18) refers to
arsenic as a strong carcinogen and made mention
of the latency period, which he based on the time
in which cellular fermentation increases after
damaging of cellular respiration. Bungeler (19)
concluded that arsenic in small amounts for
long periods produced a general neoplastic
tendency. Holland, McCall, and Lanz (20)
studied uptake, distribution, and rate of ab-
sorption and elimination of inhaled arsenic-74
in man. They concluded that over 50% of the
arsenic is deposited in the body and gradually
eliminated over a long period of time. The
combination of prolonged assimilation of small
amounts and slow excretion of arsenic by the
skin coincides well with the long latency period
required for the development of cutaneous and
internal cancer in patients with Bowen's disease
and arsenical keratosis. In our group of patients
the continued source of small amounts of arsenic
from the air, soil, food, cigarettes, occupational
contact, and some medicinal agents, and its
recognized slow excretion would account for
our findings.
Our observations and those of others point
out the variability in chemical determinations
of arsenic from patient to patient and in multiple
lesions from the same patient. No relationship
could be established between arsenic values
and different anatomic sites; however, 5 of the
11 patients with Bowen's disease who had
arsenic values of 10 pg/g had lesions of the
head and neck region. Arsenic is apparently
deposited erratically in the epithelial structures of
the skin. Tn our study this factor was minimized
by the large number of lesions examined from
50 Bowen's patients and 119 control patients.
The absence of arsenic in Bowen's lesions noted
by Domonkos (15) and Fergusson et al. (12),
although contradictory to our determinations,
can be explained on the basis of the small number
of lesions analyzed by them and the variable
results found in our study and in those of others.
In the majority of patients in our study, the
lesions had arsenic values either higher than or
within the same range as those of the immediate
adjacent skin. In the control group when the
lesion had normal amounts of arsenic the con-
tent in the immediate adjacent skin also was
within normal range, but this was not true of
the patients with Bowen's disease. Only in
rare instances did the adjacent skin contain
increased amounts of arsenic while the content
in the lesion was within the normal range.
These determinations are in agreement with
those of other investigators (11, 13, 14, 16).
In the majority of patients with Bowen's disease
who had amounts of arsenic elevated above
normal in their lesions, the time period between
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onset of the lesion and excision ranged from
approximately 1 to 10 years; however, there
was wide variability in the arsenic values, within
and beyond this time period.
Some interesting observations were made of
the lesions from our control group of patients.
Our data indicate that in lesions and adjacent
normal skin, arsenic is present in the normal
range in a significantly greater proportion of
control patients than in Bowen's patients. The
majority of the control lesions represent diseases
showing as much or more epithelial proliferation
than is seen in Bowen's disease. These observa-
tions support the concept that the Bowen's
lesion is able to concentrate arsenic.
It seems significant that of five patients with
lesions of adenoacanthoma the only lesion with
an increased arsenic value was from a patient
who also had Bowea's disease; the tissue from
the Bowen's lesion was not available for analysis.
The presence of increased amounts of arsenic
in 10 (59%) of 17 patients with senile keratosis
might in part account for the increased incidence
of primary internal cancer noted in this group
and reported by two of us (1) in 1959. It would
seem that this is more than just a coincidence.
It is suggested that even though Bowen's disease
and senile keratosis have many different clinical
and histological features, they may be biologically
related. Because of these observations regarding
senile keratosis, we plan to study a much larger
group of patients and report the results at a
later date.
SUMMAEY AND CONCLUSIONS
The determinations from analysis for arsenic
content in cutaneous lesions of Bowen's disease
from 50 adult patients are presented in this
study. Normal skin and a variety of cutaneous
lesions and diseases from 126 patients were
similarly analyzed. Ninety-five per cent of the
Bowen's and control patients had no previous
history of arsenic intake. Our data indicate
that in lesions and in the adjacent skin, arsenic is
present in increased amounts in a significantly
greater proportion of Bowen's patients than in
the lesions of the control patients. On the basis
of our study, the Bowen's lesion usually con-
centrated arsenic more than did the control
lesions. In the majority of patients, the lesions
had arsenic values higher or the same as those of
the normal adjacent skin. In patients with
multiple lesions from different parts of the body,
we noted individual variations in the arsenic
content of different lesions. No striking relation-
ship could be established between arsenic values
and different anatomic sites. The histopathologie
changes in routine sections were of value in
determining possible histogenesis and patho-
genesis of the Bowen's lesion. The epithelial
tissue involved in Bowea's disease is probably the
undifferentiated cell of the external root sheath
of the pilosebaceous apparatus.
Our observations strongly suggest that arsenic
could be one of the causes of Bowen's disease
and that the internal and cutaneous cancer
present in these patients may well represent the
systemic manifestations of this strong chemical
carcinogen.
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DISCUSSION
DR. HERMAN BEEP.MAN (Philadelphia, Pa.):
I think Doctors Graham and Helwig and their
Colleagues have done a service in calling our
attention to this phenomenon; but being an old
hand at arsenical determinations in tissues and
knowing the variability of the technies that have
been used, I think perhaps some of the differences
in the results may be due to technical factors
in the method used.
DR. WALTER F. LEVEE (Boston, Massa-
chusetts): I think the figures presented are very
impressive; but, of course, there is the question of
interpretation.
It was pointed out already that one cannot
exclude the possibility that the storage of arsenic
is a secondary process. It is known that kcratin
is particularly prone to store arsenic. Could it
not be that a lesion of Bowcn's disease stores
arsenic to such a preponderance mainly because
it contains a good deal of kcratin and dyskeratotic
cells?
I would like, therefore, to ask the presenter
the question if he has investigated the arsenic
content of lesions of squamous cell carcinoma of a
rather high degree of maturity and of lesions of
keratoacanthoma in which also a good deal of
keratin is present.
DR. EVERETT C. Fox (Dallas, Texas): This
has been a very interesting presentation and I
have been interested in this subject for many
years, having seen a patient with Bowen's
disease on two occasions who had papillary
lesions of the bladder that were recurrent and
one became earcinomatous.
In 1932, the late Nelson Paul Anderson pub-
lished his paper on basal cell carcinoma in
miners, many with arsenical keratoses. Through
the years, many of us as clinicians can recognize
what we call arsenical carcinoma, the basal cell
lesions of the chest and back. And when we can
get an adequate history, we usually have a
history of an ingestion of Fowler's solution. That
is the more common of the arsenicals, at least
in the South, that was used as a family tonic like
quinine. We still see a fair number of these
cases.
At our VA Hospital at the present time, they
are running some very interesting studies on
bronchiogenic carcinoma, an investigation of
arsenic in cigarettes.
So, arsenic is still being implicated in many of
our malignancies and it is well worth further
study.
FE. ANTHONY N. DoMoNKos (New York,
N. Y.): I enjoyed this paper very much. A similar
work was done by me several years ago consisting
of a quantitative determination of arsenic in the
skin. (Neutron Activation Analysis of Arsenic in
Normal Skin, Keratoses and Epitheliomas, Arch.
Derm. 80: 672—677 (Dec.) 1959.)
Of the 180 skin specimens quantitated for
arsenic by neutron activation analysis there are
5 specimens of Bowen's disease from patients
with arsenic history and 2 without an arsenical
ingestion history. Although no conclusive re-
sults can be obtained from the analysis of 5
specimens, there was a wide enough variation in
the amount of arsenic of these specimens to
make it unfeasible for the acceptance of any
conclusion. On the basis of the findings in the
normal skin, kcratoscs and epithcliomas with or
without arsenic history I had to conclude that
there is no correlation in the amount of arsenic
found in any of the groups of skin studied.
Although I am convinced that arsenic may
cause Bowcn's disease, arsenical keratoses and
arsenical epitheliomas, I do not believe that the
amount of arsenic found in these lesions or in
normal skia is of any significance. Therefore,
qualitative or quantitative determinations for
arsenic in the skin or the blood are of no diagnostic
or pathogenetic value.
DR. PETER FLE5CH (Philadelphia, Pennsyl-
vania): How could you be certain that you had
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relatively similar amounts of epidermal and
dermal tissue in your specimens, because, arsenic
could be expected to accumulate primarily in
the epidermis?
Da. MARCUS R. CARO (Chicago, Illinos):
I am very glad to see this clinical and histo-
chemical confirmation of conclusions which I
reached by deduction some time ago. It has
long been my impression that the association of
Bowen's disease with internal primary cancer in
individuals is not an indication of a cancerous
diathesis, but it merely means that the Bowen's
disease is a cutaneous manifestation of the
carcinogenic effect of arsenic in people in whom
the same arsenic produces cancer in internal
organs.
It is not at all surprising that in some of these
patients the amount of arsenic present in the
adjacent skin was much higher than it was in
the Bowen's disease or other cancers present.
It must be remembered that the arsenic is
deposited in the skin at the time it is ingested or
absorbed. The cancer generally develops many
years later, long after the patient has stopped
ingesting arsenic.
Now, the total amount of arsenic present in a
cancer or Bowen's disease should not be any
greater than the amount of arsenic that was
present at that site at the time the cancer de-
veloped. And, because of that, on a proportional
basis there should be much less arsenic present
in the tissue of the cancer than in the adjacent
skin where you still have the full amount of
arsenic that was deposited at the time.
Now, there are many sources of arsenic which
are sometimes overlooked. I saw a patient just
recently with multiple arsenical carcinomas, and
in him I found that since childhood he has been
taking Dr. Gay's mixture for asthma; and he is
still getting it. I don't know what the situation
is in New York, but in Chicago many drug stores
still sell over the counter bottles of Gay's mixture
for asthma and hayfever and this contains Fow-
icr's solution.
At times patients get Chinese pills or Asiatic
pills which contain arsenic trioxide, and these
are often taken by patients without the knowl-
edge of a physician. I have seen several instances
where the doctor did not know that the patient
was taking Chinese pills for asthma.
Also, in Chicago many, many years ago, it was
found by one of our prominent neurologists that
patients with epilepsy who were given bromides
developed bromide acne; but if Fowler's solution
was added to the bromides, acne did not de-
velop; and even though that goes back at least
fifty years, I am still now seeing patients with
arsenical cancers who took bromides with arsenic
for epilepsy many, many years ago. They didn't
get acne, but they have arsenical cancers now.
Da. GERD K. STEIGLEDER (New York, New
York): I think there is on observation by Wels
and his coworkers (Arch. exp. Path. u. Pharmak.
208: 116, 1949) which should be considered.
These investigators injected the salts of heavy
metals in the blood vessels of the ear of pigs.
When the ear was exposed to sunlight, the
heavy metals were deposited in the epidermis in
macroscopically visible amounts.
In other words, there may be an additional
factor in some areas of the body which leads to
deposit of arsenic which may not be present in
others.
Dn. JAMES H. GRAHAM (in closing): I could
read another paper in answer to the interesting
and thought provoking questions.
Dr. Beerman brought up the question about
variability of results in relationship to reliability
of the various methods. Certainly the neutron
activation analysis method is highly sensitive
and accurate. Dr. Domonkos, I am sure will
agree and can tell you more about that method.
The various other technics used for analysis of
arsenic in tissue are well established in the litera-
ture by such workers as Kingsley and Schaffert,
Evans and Bandemer, Oliver and Funnel, and
others.
In our study, if arsenic was present in the
lesion in large amounts, this increase could be
detected in even small pieces of tissue. This
seems to indicate that the methods we used are
specific for arsenic and that sensitive technics for
demonstration of minute amounts of arsenic is
not necessary. We ran all tissue specimens
through as unknowns and in addition, controls
(known amounts of arsenic) to check for constant
accuracy and reliability of our methods.
I think that the various methods including those
used in our laboratory are reliable and accurate.
In answer to Dr. Lever's question about
whether Bowen's disease just happens to in-
cidentally store arsenic and its presence, is not
of significance. We studied a wide variety of
benign, premalignant and malignant lesions,
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including many with prominent epithelial pro-
liferation such as squamous cell carcinoma, basal
cell carcinoma and keratoacanthoma. These
lesions did not contain increased values of arsenic
in significant amounts when compared with that
in Bowen's disease.
Dr. Fox referred to Dr. Nelson Paul Ander-
son's report in 1932. I think Dr. Anderson
probably deserves some of the original credit
for calling to our attention the clinical and
microscopic similarities of lesions of arsenical
keratosis and Bowen's disease. He suggested
that the 2 processes were probably the same
disease.
The variability of results mentioned by Dr.
Domonkos was also observed in our study.
Almost everyone who has analyzed premalignant
and malignant cutaneous lesions, has noted this.
We feel, that this factor was overcome by the
large number of Bowen's lesions and control
lesions analyzed in our study. In other words,
the increased values of arsenic in 82% of the
Bowen's lesions are compared to 30% in the
control lesions is of statistical significance. Large
numbers are needed for significant results.
In answer to Dr. Flesch's question, we dis-
sected practically all the dermis away from the
Bowen's lesion prior to analysis and feel that the
arsenic is deposited mainly in the epidermis.
We analyzed a number of soft tissue tumors and
found no appreciable amounts of arsenic.
In comment to Dr. Caro's remarks, there is
still a lot of arsenic in our environment. Arsenic
may be found in the air, soil, food, tobacco and
some medicinal agents.
Arsenic assimilated in the body in small
amounts over a long period is an epithelial
carcinogen, whereas larger single amounts will
kill the cells. Small amounts of arsenic gradually
alter cellular metabolism from respiration to
fermentation.
We have also wondered about sunlight as a
possible co-carcinogen because several of the
Bowen's lesions with increased amounts of
arsenic involved the head and neck region.
